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Alk1 and Alk5 inhibition by Nrp1 controls vascular
sprouting downstream of Notch
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Sprouting angiogenesis drives blood vessel growth in healthy and diseased tissues. Vegf and
Dll4/Notch signalling cooperate in a negative feedback loop that specifies endothelial tip and
stalk cells to ensure adequate vessel branching and function. Current concepts posit that
endothelial cells default to the tip-cell phenotype when Notch is inactive. Here we identify
instead that the stalk-cell phenotype needs to be actively repressed to allow tip-cell forma-
tion. We show this is a key endothelial function of neuropilin-1 (Nrp1), which suppresses the
stalk-cell phenotype by limiting Smad2/3 activation through Alk1 and Alk5. Notch down-
regulates Nrp1, thus relieving the inhibition of Alk1 and Alk5, thereby driving stalk-cell
behaviour. Conceptually, our work shows that the heterogeneity between neighbouring
endothelial cells established by the lateral feedback loop of Dll4/Notch utilizes Nrp1 levels as
the pivot, which in turn establishes differential responsiveness to TGF-b/BMP signalling.
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V
ascular sprouting is critical for the formation of blood
vessel networks during embryonic development and in the
physiological response to hypoxia or tissue injury in the
adult1. Activated endothelial cells display heterogeneous gene
expression, morphology and cell behaviour as they collectively
engage in the morphogenetic process of sprout formation2.
Vascular endothelial growth factor A (Vegf-A) stimulates
endothelial migration and proliferation3, but while some form
polarized filopodia protrusions and acquire the leading tip
position in the nascent sprout (tip cells), neighbouring cells
contribute to elongation and stability of the new vessel
(stalk cells)4. The specification of tip and stalk cells is regulated
by Dll4/Notch signalling1. Genetic and pharmacological
studies led to the current concept that the tip cell phenotype is
the default response of endothelial cells, whereas the stalk
cell is actively inhibited from forming tip cells through the
activity of Notch. Mosaic analysis illustrated that cells deficient
in Notch signalling dominate the tip position, whereas
Notch-activated cells are excluded from the tip position5,6.
Dynamic observations identified that endothelial cells compete
for the tip cell position by virtue of differential Vegfr levels
under control of Dll4/Notch signalling7,8. All three Vegf
receptors contribute to tip/stalk cell competition, but Notch
signalling inhibition normalizes the contribution of Vegfr-
deficient cells at the tip, indicating that Vegf receptors act
upstream of Notch.
Notch downstream effectors driving stalk cell behaviour are
attractive targets to prevent excessive angiogenesis in cancer and
ocular neovascular disease. A recent study has suggested that the
Sox17 transcription factor promotes stalk cell behaviour down-
stream of Notch; however, another study using similar genetic
mouse models reports opposite findings, indicating that the role
of Sox17 in tip–stalk cell specification and its relationship with
Notch1 may be context dependent9.
In parallel to Notch, Bmp/Smad1/5 signalling prominently
affects tip/stalk specification. Inhibition of Alk1 or endothelial-
specific Smad1 and Smad5 deletion leads to hypersprouting in
embryonic and postnatal development. Bmp9 and Bmp-10 inhibit
sprouting angiogenesis by activating Notch downstream target
genes leading to stalk cell specification10–13. Tgf-b also inhibits
sprouting angiogenesis but exhibits differential effects depending
on the involvement of the Tgf-b type-1 receptors Alk1 or Alk5
(refs 14–18). The identity of the signal required to turn Bmp/Alk1
signalling off in tip cells, and whether Alk5 signalling regulates
tip/stalk specification, remains unknown. Furthermore, the link
between Notch and the Smad signalling pathway in tip/stalk
competition has not been identified.
Neuropilin-1 (Nrp1) is a transmembrane receptor that
binds several structurally and functionally unrelated classes of
ligands, including class-3 semaphorins, Vegf family members and
Tgf-b19,20. Identified as a co-receptor for semaphorin/PlexinD
signalling21 and Vegf-A/Vegfr2 signalling22, it is expressed in the
angiogenic vasculature including the tip cells and has been
implicated in tip cell function and guidance in the embryo23–26.
Nrp1 can enhance Vegf-driven signalling through Vegfr2 via
interactions between synectin, an adaptor that binds the
PDZ-binding site in the Nrp1 cytoplasmic domain, and Vegfr2
(ref. 27). Following Vegf binding, the Nrp1–Synectin–Vegfr2
complex is internalized into endosomal compartments, where
Vegfr2 is protected from dephosphorylation, leading to sustained
Erk activation and arteriogenesis28. Consequently, mice carrying
a targeted deletion of the Nrp1 cytoplasmic domain show
impaired arteriogenesis28. Notably, however, neither Nrp1cyto
mice, nor mice deficient for Synectin show any angiogenesis
defects29,30, suggesting that Nrp1 drives sprouting angiogenesis
through other signalling mechanisms.
Here we report that Nrp1 functions as a Notch effector and
links Notch with Tgf-b/Alk5 and Bmp9/Alk1 signalling to
regulate endothelial competition for the tip position. Nrp1 cell
autonomously and quantitatively determines the ability of cells to
become tip cells even in the absence of Notch signalling. Loss of
Nrp1 renders the vasculature completely refractory to the loss of
Notch, demonstrating that Nrp1 is the most critical determinant
of tip cell formation and function known to date. Loss-of-
function and gain-of-function experiments identify that Nrp1
negatively regulates Smad2/3 activation downstream of Tgf-b and
Bmp9 signalling. Genetic inactivation of Alk5 and Alk1 rescues
the ability of Nrp1-deficient cells to contribute to the tip position.
We propose that Notch-mediated differential expression of Nrp1
critically regulates tip/stalk specification and thus vascular
branching by modulating the activity of Tgf-b/Alk5 and
Bmp9/Alk1 signalling between neighbouring endothelial cells.
Results
Differential Nrp1 expression drives tip cell competition. To
determine the functional importance of Nrp1 expression levels in
sprouting angiogenesis and tip cell formation, we established
chimeric mice, and chimeric embryoid body (EB) sprouting
assays combining cells homozygous or heterozygous for a
Nrp1-null/lacZ reporter allele (Nrp1lacZ/lacZ or Nrp1lacZ/þ ,
respectively) with wt cells, expressing the marker DsRed.
Nrp1lacZ/lacZ or Nrp1lacZ/þ cells were markedly outcompeted by
wild-type (wt) cells at the tip position, demonstrating that Nrp1
levels are critical for tip formation (Fig. 1a–c; Supplementary
Fig. 1a–c). We also induced endothelial Nrp1 deletion
during postnatal retinal angiogenesis by crossing Nrp1fl/fl31 and
Cdh5-CreERT2 mice32,33. Tamoxifen-mediated recombination
efficiently reduced Nrp1 protein levels, decreased radial
expansion and reduced sprouting/branching (Supplementary
Fig. 1d–m), illustrating that Nrp1 is critical for sprouting and
branching during postnatal angiogenesis.
Low-dose tamoxifen injection in conditional Nrp1fl/fl;
Cdh5-CreERT2 crossed with mTmG Cre-reporter mice34
produces recombination of the Nrp1 floxed allele and the
mTmG reporter allele in a subset of green fluorescent protein
(GFP)-positive cells. In samples where around 80% of retinal
endothelial cells were GFP positive, and therefore have
experienced Cre activity, only 3% of Nrp1fl/fl homozygous cells
are found at the capillary tip (Fig. 1d–f). Moreover, heterozygous
Nrp1fl/þ ; mTmG; Cdh5-CreERT2 retinas also showed an under-
representation of Nrp1 heterozygous cells in the tip position
(Fig. 1g–i), despite only a slight decrease in overall vessel
branching (Supplementary Fig. 2a–d) and no effect on
proliferation (Supplementary Fig. 2e–i).
Nrp1 drives tip cell competition independent of Dll4. As
Vegfr2 levels regulate Dll4 (ref. 7), and Nrp1 is considered a co-
receptor for Vegf-A/Vegfr-2 (ref. 22), we investigated whether
Nrp1 levels influence Dll4 levels. We found no differences in Dll4
staining between Nrp1-expressing and -deficient cells in chimeric
EBs, as well as in complete or mosaic deficient retinas (Fig. 2a;
Supplementary Fig. 3). Furthermore, overall Dll4 mesenger RNA
and protein levels were not significantly affected in Nrp1lacZ/lacZ
EBs and human umbilical vein endothelial cells (HUVECs)
transduced with Nrp1 short interfering RNA (siRNA) or over-
expressing Nrp1–GFP (Fig. 2b–d), and Notch1 expression and its
target Hey1 were unchanged (Fig. 2e). In contrast, inhibiting
Notch signalling in HUVECs using the g-secretase inhibitor
DAPT led to upregulation of Nrp1 in a time-dependent manner
(Supplementary Fig. 4a,b). Similarly, we observed increased
Nrp1 expression in EBs upon DAPT treatment (Supplementary
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Fig. 4c,d). The Notch-mediated downregulation of Nrp1 together
with the observation that already a 50% gene dose reduction
renders endothelial cells unable to form tip cells although Dll4
expression is unaffected, suggests that Nrp1 functions not
upstream, but as a downstream effector of Notch activity in
tip/stalk formation.
Nrp1 acts as a downstream effector of Notch. To test this
prediction, we investigated whether Notch inhibition by DAPT,
which leads to marked hypersprouting in wt retinas5,35–37, can
restore sprouting in the Nrp1-deficient vasculature. Remarkably,
the Nrp1-deficient retinal vasculature did not respond to DAPT
treatment with hypersprouting nor did DAPT rescue the
outgrowth or branching defects, demonstrating that Notch
inhibition is not able to induce excessive tip cell formation in
the absence of Nrp1 (Fig. 3a–d). Furthermore, DAPT treatment
of mosaic retinas or chimeric EBs failed to restore the ability of
heterozygous or homozygous cells to reach the tip position
(Fig. 3e–k; Supplementary Fig. 4e–g). Thus, unlike Vegfr2
heterozygous cells, which regain the tip position upon Notch
inhibition7, Nrp1 heterozygous and homozygous deficient cells
stay confined to the stalk position.
To directly determine whether Nrp1/Vegfr2 co-receptor
activity is functionally involved in tip cell competition, we
generated chimeric EBs mixing Vegfr2 (ref. 7) and Nrp1
heterozygous cells. If Vegfr2 co-receptor function accounted for
tip cell formation, we expected equal handicap of Vegfr2þ / and
Nrp1þ / cells to reach the tip. Surprisingly, we found that Nrp1
heterozygous cells are not able to acquire the tip position even
when competing against Vegfr2 heterozygous cells (Fig. 4a–c).
Again Notch inhibition was ineffective in restoring the balance at
the tip (Fig. 4d–f). Thus a 50% gene dose reduction in Nrp1
impedes tip cell formation even when cells have twice the Vegfr2
level than their competing neighbours and when Notch is
inactive. We conclude that unlike Vegfr2, Nrp1 does not operate
upstream of Dll4/Notch and that Vegfr2 co-receptor function is
unlikely to contribute to Nrp1 signalling events that regulate tip
cell competition.
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Figure 1 | Differential Nrp1 levels affect tip cell competition. (a–c) Retinal vessels from a wild-type host expressing DsRED injected with Nrp1Lacz/þ
ES cells, assayed at postnatal day P5. (a) Representative overview of the sprouting front; scale bar, 420mm. (b) Segmented images showing wt nuclei
(white) and nuclei from Nrp1lacZ/þ cells (green), using Erg staining; scale bar, 20mm. (c) Quantification of tip cell contribution normalized to overall
contribution of cells to the endothelium, Po0.0001 compared with wt cells injected retinas. (d–i) Retinas of Nrp1fl/fl; mTmG; Cdh5-CreERT2 and Nrp1fl/þ ;
mTmG; Cdh5-CreERT2 mice injected with 30 mg tamoxifen at P1, retinas were assayed P5. (d,g) Representative overview of the sprouting front, scale bar,
100mm, and higher magnification, scale bar, 20mm (e,h). Unrecombined, wt cells are labelled with Isolectin-B4 only; recombined Nrp1-deficient cells
express GFP. (f,i) Quantification of recombined Nrp1-deficient cells at the tip, normalized to overall contribution of cells to the endothelium. Statistical
significance was determined by comparing the proportion of Nrp1-deficient (green) cells at the tip with the total proportion of Nrp1-deficient cells;
Po0.001 (f), Po0.0015 (i). n¼ the number of retinas analysed; n¼4 (c), n¼ 3 (f) and n¼ 6 (i). Values represent mean±s.e.m. Statistical significance
was assessed using a Student’s unpaired t-test.
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Nrp1 affects Smad2/3 activation. The Tgf-b pathway is known
to inhibit sprouting, and Tgf-b has been shown to bind to Nrp1
in T cells and in cancer cells16,17,20,38. Its downstream effector
Smad2 showed differential activation in EB sprouts, with strong
nuclear staining in the stalk cells, but little or no pSmad2 in tip
cells (Fig. 5a). Treatment with recombinant Tgf-b or the Alk5
inhibitor SB-431542 abolished the differential nuclear localization
of pSmad2 (Fig. 5b,c).
To test whether Nrp1 influences Tgf-b-induced signaling, we
measured Smad2 phosphorylation after stimulation with Tgf-b.
Reduced Nrp1 expression in siRNA-treated HUVEC (Fig. 5d,e)
or Nrp1-deficient EB (Supplementary Fig. 5a,b) consistently led
to increased Smad2 phosphorylation. Conversely, overexpression
of Nrp1 in HUVEC reduced pSmad2 levels compared with
control-plasmid-transfected cells (Fig. 5f,g).
Phosphorylation of the Smad linker region (Ser 245/250/255),
which is known to be induced after growth factor stimulation
and might inhibit Smad activation, was unaffected by
Nrp1 knockdown (Fig. 5h,i). However, C-terminal phosphoryla-
tion of Smad3 was also increased after Nrp1 knockdown
(Fig. 5j,k), together indicating that Nrp1 levels quantitatively
affect Tgf-b signalling via modulation of Smad2/3
phosphorylation.
Nrp1 knockdown also increased Smad2/3 activation in
response to Bmp9, but did not affect phosphorylation of
Smad1/5/8 in response to BMP9 or Tgf-b (Fig. 5l,m;
Supplementary Fig. 5c–e). Thus, Nrp1 tonically suppresses
Smad2/3 activation upon Tgf-b or Bmp9 stimulation.
The expression of Smad target genes, including JunB, which
can be activated through Tgf-b and Bmp2 (refs 39–41), cJun42,
Smad6 and Smad7 (ref. 43), Id1 (refs 44,45), Id3 (ref. 46), Hey1
(refs 10,11) and Hes1 (refs 10,11) were increased in HUVEC cells
deficient for Nrp1, when stimulated with Tgf-b. In contrast, the
expression of Apln, a gene that is upregulated in tip cells47, is not
affected by the loss of Nrp1 when HUVEC cells were stimulated
with Tgf-b (Fig. 6a–d; Supplementary Fig. 6a–e). Lack of Nrp1
also failed to affect Tgf-b or Bmp9 receptor expression
(Supplementary Fig. 6f,g).
We next tested which domain of Nrp1 is critical for its effect on
endothelial Smad activation. HUVECs transfected with constructs
lacking either the C-terminal SEA domain that binds to PDZ
adaptors48 or the entire cytoplasmic tail show a similar reduction
of Tgf-b-induced Smad2 phosphorylation as the full-length
construct (Fig. 6e,f). However, recombinant extracellular Nrp1
(ref. 49) did not reduce pSmad2 upon Tgf-b stimulation
(Fig. 6g,h). We conclude that the extracellular and
transmembrane domain of Nrp1 quantitatively regulates the
endothelial response to Tgf-b.
Alk5/Alk1 inhibition rescues sprouting in Nrp1-deficient cells.
To investigate the functional impact of Alk/Smad2/3 signalling on
sprouting behaviour and tip cell formation, we utilized a mosaic
HUVEC in vitro tip cell competition assay9. When control
siRNA- and NRP1-siRNA-transfected cells were mixed, more
than 80% of tips were occupied by control siRNA-transfected
cells (Supplementary Fig. 7a,b). In contrast, cells transfected with
siRNAs against ALK1, ALK5 or SMAD2/3 preferentially occupy
the tip position. Strikingly, simultaneous knockdown of NRP1
together with ALK1, ALK5 or SMAD2/3 normalized tip cell
contribution (Supplementary Fig. 7a,b). Treatment of mosaic
HUVEC sprouting assays, chimeric EBs or mosaic Nrp1fl/fl;
mTmG; Cdh5-CreERT2 mice with Alk5 inhibitor SB-431542
restored the ability of Nrp1-deficient cells to reach the tip position
(Supplementary Fig. 7c–j). SB-431542 also partially restored
sprouting in Nrp1-deficient EBs (Supplementary Fig. 8).
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Figure 2 | Nrp1-deficient cells express Dll4. (a) Representative image of
Dll4 expression in endothelial cells at the vascular front of mice carrying
endothelial-specific Nrp1 deletion, scale bar, 20mm. Mice were injected with
30mg of tamoxifen at P1. Tip cell outline is indicated by a dashed line.
Dll4 expression was comparable between Nrp1-deficient, GFP-positive
cells and Nrp1-positive, GFP-negative cells. (b) P4 HUVEC cells transfected
with control siRNA, NRP1 siRNA, control-GFP construct and NRP1–GFP–His-
construct. NRP1 and DLL4 protein levels were assessed 24 h after
transfection by western blot (two individual experiments). Full western
blots are shown in Supplementary Fig. 9. (c) Quantification of DLL4 protein
expression normalized to TUBA4A, a representative of two experiments is
shown. (d,e) Real-time quantitative PCR for Dll4 (d) and Notch/Hey1 (e)
from 2D EBs derived from wt cells, Nrp1lacZ/þ cells and Nrp1lacZ/lacZ
cells. Experimental triplicates were performed; represented values were
normalized to Pecam expression and wt transcription levels. Values indicate
mean±s.d.
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To directly investigate the interaction between Nrp1 and
Alk1/Alk5 in vivo, we generated compound Nrp1fl/þ ; Alk5fl/þ ;
mTmG; Cdh5-CreERT2 mice. Upon low-dose tamoxifen treat-
ment, 33.3% of Nrp1/Alk5-deficient cells were found at the tip
position (Fig. 7a,b,g), as opposed to 11.9% of single-Nrp1
heterozygote cells (Fig. 1i). Thus, deleting one copy of Alk5
partially rescues the capacity of Nrp1 heterozygous cells to attain
the tip position. Interestingly, however, Alk5 deficiency alone in
mosaic Alk5fl/fl; mTmG; Cdh5-CreERT2 retinas did not promote
preferential tip cell localization (Fig. 7c,h), indicating a strong and
Mock
GFP IB4 GFP IB4
DAPT
GFP IB4
DAPT
87.5% wt tip
12.5% Nrp1lacZ/+ tip
51.6% wt
48.4% Nrp1lacZ/+
95.1% wt tip
4.9% Nrp1–/– tip
17.2% wt
82.8% Nrp1–/– 
Mock
IB4
DAPT
IB4
Mock
IB4
DAPT
IB4
DsRED-wt cells
wt nuclei Nrp1lacZ/+ nuclei
IB4
IB4 DsREDErg
DAPTNrp1fl/fl
Nrp1fl/fl;Cdh5-CreERT2 Nrp1fl/fl;mTmG;Cdh5-CreERT2
50%
0%
100%
n=6
%
 O
f c
el
ls 
at
 ti
p 
po
sit
io
n
n=6DAPT
%
 O
f e
nd
ot
he
lia
l c
on
tri
b.
P<0.0001
n=3
P<0.0013
%
 O
f c
el
ls 
at
 ti
p 
po
sit
io
n
0%
100%
%
 O
f e
nd
ot
he
lia
l c
on
tri
b.
50%
n=3
DAPT
Figure 3 | Nrp1 acts as downstream effector of Notch. (a–d) Representative images of the Isolectin-B4-stained retinal vasculature, of P5 Nrp1fl/fl and
Nrp1fl/fl; Cdh5-CreERT2 mice, injected with 100mg tamoxifen at P1/P2 and treated with 100mg kg 1 DAPT at P4; scale bar, 100mm. (a) Retinal vessels of
Nrp1fl/fl mice; (b) DAPT treatment of Nrp1fl/fl; (c) Nrp1fl/fl; Cdh5-CreERT2; (d) DAPT-treated Nrp1fl/fl; Cdh5-CreERT2 mice. n¼ number of retinas examined;
n¼4 (a), n¼4 (b), n¼6 (c) and n¼ 6 (d). (e–g) P5 retinal vasculature of wt blastocysts expressing DsRED injected with Nrp1lacZ/þ ES cells, treated with
DAPT (100mg kg 1) at P4. (e) Representative overview of the sprouting front; scale bar, 420mm. (f) Segmented images; wt nuclei (white) and Nrp1lacZ/þ
nuclei (green); scale bar: 20mm. (g) Quantification of Nrp1lacZ/þ cells at the tip, normalized to overall contribution of cells to the endothelium; n¼6
(number of retinas analysed); Po0.0001. (h–k) P5 retinas of Nrp1fl/fl; mTmG; Cdh5-CreERT2 mice injected with 30 mg tamoxifen at P1, and treated with
100mg kg 1 DAPT at P4. Unrecombined wt cells are labelled with Isolectin-B4 only; recombined Nrp1-deficient cells express GFP. (h) Representative
overview of MOCK control. (i) Representative overview of DAPT-treated animals; scale bar, 100 mm, magnification is shown in j; scale bar, 20mm.
(k) Quantification of recombined Nrp1-deficient cells at the tip, normalized to overall contribution of cells to the endothelium. Statistical significance was
determined by comparing the proportion of Nrp1-deficient (green) cells at the tip with the total proportion of Nrp1-deficient (green) cells; n¼ 3 (number of
retinas analysed); Po0.0013. (g,k) Values represent mean±s.e.m. Statistical significance was assessed using a Student’s unpaired t-test.
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selective genetic interaction between Alk5 and Nrp1 in the
process of tip cell selection.
To determine whether Bmp9-Alk1 signalling also contributed
to the effects of Nrp1 inhibition in vivo, we generated Nrp1fl/þ ;
Alk1fl/fl; mTmG; Cdh5-CreERT2 mice. Upon low-dose tamoxifen
treatment, 28.1% of Nrp1/Alk1-deficient cells were found at the
tip position (Fig. 7d,e,i), as opposed to 80.1% single-Alk1
homozygous cells (Fig. 7f,j). In addition, hypervascularization
seen in endothelial Alk1fl/fl mutants appeared strikingly
normalized by deletion of one allele of Nrp1. Thus, while
single-Alk1- and Nrp1-deficient cells show strong preference for
tip and stalk, respectively, reducing Nrp1 levels in Alk1 mutants
by 50% efficiently normalizes tip cell contribution and vascular
patterning.
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Figure 4 | Nrp1 deficiency overrules Vegfr2 deficiency during tip cell competition. (a,b,d,e) Representative confocal images of the sprouting vasculature
of a chimeric EB composed of Vegfr2GFP/þ cells and Nrp1Lacz/þ cells. Untreated (a,b) or treated with 5mMDAPT for 5 days until harvesting at day 10 (d,e).
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represent mean±s.e.m.
Figure 5 | Nrp1 influences Smad2/3 activation. (a–c) Representative confocal images of wt sprouts from EBs immunolabelled for pSmad2. The outline of
the wt sprouts is indicated with a dashed line using the endogenous DsRED marker. DAPI staining (not shown) was used to mark nuclei (blue line). Sprouts
from (a) untreated EBs, (b) treated with 2 ngml 1 Tgf-b for 1 h and(c) treated with 10mM SB-421543 for 4 h. Scale bar, 13 mm. (d,e) Western blot analysis
of proteins from P4 HUVEC transfected with control siRNA and NRP1 siRNA, with or without stimulation with 2 ngml 1 TGF-b for 1 h. Full western blots
are shown in Supplementary Fig. 10. A representative blot of six is shown; P¼0.0012 NRP1 siRNA compared with control. (f,g) Proteins from P4 HUVEC
transfected with control-GFP and NRP1–GFP–His construct for 24 h, with or without stimulation with 2 ngml 1 TGF-b for 1 h were assessed for SMAD2
phosphorylation. Full western blots are shown in Supplementary Fig. 11. A representative blot of four is shown; P¼0.0017 NRP1 overexpression compared
with control. (e,g) Quantification of pSMAD2 protein normalized to SMAD2/3. (h–k) Western blot analysis of proteins from P4 HUVEC transfected with
control siRNA and NRP1 siRNA, with or without stimulation with 2 ngml 1 TGF-b for 1 h. Full western blots are shown in Supplementary Figs 12 and 13.
(i) Quantification of pSMAD2 protein normalized to SMAD2/3; P¼0.0848 Nrp1 siRNA compared with control. (k) Quantification of pSMAD3 protein
normalized to SMAD3; P¼0.0181 NRP1 siRNA compared with control. (l,m) Western blot analysis of P4 HUVEC transfected with control siRNA and NRP1
siRNA, with or without stimulation with 10 ngml 1 BMP9 for 15 and 30min. Full western blots are shown in Supplementary Fig. 14. A representative blot of
four is shown. (m) Quantification of pSMAD2/3 protein normalized to SMAD2; Po0.0011 NRP1 siRNA compared with control. All values represent
mean±s.e.m. DAPI, 4,6-diamidino-2-phenylindole; NS, not significant.
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Discussion
In summary, our mosaic studies reveal that the loss of only
one allele of Nrp1 renders cells unable to compete with wt cells
for the tip cell position, in the absence of major vascular
phenotypes in heterozygous mice. Importantly, mosaic in vivo
deletion by induced Cre activation and blastocyst injections to
create chimerism that does not rely on Cre reporters both
independently validated the principal finding that Nrp1
heterozygous cells are not able to compete for the tip. Further
validation was achieved using the EB system and in HUVEC
spheroids, two more reductionist models that lack system
contributions. Remarkably, Nrp1-deficient cells are unable to
attain the tip position even when Notch is inhibited, and the loss
of Nrp1 renders the vasculature completely refractory to the loss
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of Notch. Notch inhibition normalizes tip cell contribution
in ECs deficient for Vegfr1, 2 or 3 (refs 7,8), but not in
Nrp1-deficient cells, indicating that in contrast to Vegfrs,
including Vegfr2, that act upstream of Dll4/Notch50, Nrp1
operates downstream of Notch. Given that Nrp1 is quantitatively
regulated by Notch activity51, these results identify Nrp1as the
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critical downstream effector of Notch in tip/stalk specification
during angiogenesis.
Our finding that Nrp1 has functions beyond acting as a Vegfr2
co-receptor could explain why knock-in mice expressing an Nrp1
variant that cannot bind Vegf are born at Mendelian ratios and
show only minor embryonic angiogenesis defects, while global
Nrp1 knockouts are embryonic lethal due to severely disrupted
vasculature52,53. In addition, our data show that any Vegfr2
surface regulation by Nrp1 does not affect Dll4 levels and
therefore does not operate upstream of Notch signalling in tip cell
selection. Blocking of Vegf binding to Nrp1 using a specific
antibody that leaves Vegf binding to Vegfr2 intact54 does
not phenocopy the retinal angiogenesis defects in Nrp1 mutants
described here, and Nrp1 promotes activation of intracellular
c-abl activation in a VEGF-independent manner55, further
supporting the idea that Nrp1 may affect other pathways that
trigger tip cell formation.
Our results identify a significant overactivation of the Smad2/3
pathway in Nrp1-deficient cells as the key determinant of loss of
tip cell capacity and sprouting. They are consistent with a model
in which Notch activation in stalk cells decreases Nrp1 levels,
which induces stalk cell behaviour by suppressing Smad2/3
activation downstream of Alk1 and Alk5. High levels of Nrp1
suppress Smad2/3 activation in wt tip cells, while increased
Alk1/Alk5 signalling in Nrp1 mutant endothelial cells leads to
inhibition of tip cell formation (Fig. 8).
Tgf-b has well-known effects on vessel sprouting and
stability56,57, but has not been implicated directly in tip/stalk
specification. Previous work established that Tgf-b addition to
embryonic stem (ES) cells cultures blunts sprouting17. Whereas
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Figure 7 | Inhibition of Alk5 and Alk1 rescues the Nrp1-deficient sprouting defect. Retinas of Nrp1fl/þ ; Alk5fl/þ ; mTmG; Cdh5-CreERT2 mice (a,b),
Alk5fl/fl; mTmG; Cdh5-CreERT2 mice (c), Nrp1fl/þ ; Alk1fl/fl; mTmG; Cdh5-CreERT2 mice (d,e) or Alk1fl/fl; mTmG; Cdh5-CreERT2 mice (f) injected with 30mg
tamoxifen at P1; retinas were assayed P5. Unrecombined wt cells are labelled with Isolectin-B4 only; recombined cells express GFP. Magnification of a is
shown in b, magnification of d is shown in e; scale bar, 100 mm (a,c,d,f), 20mm (b,e). Quantification of recombined Nrp1fl/þ ; Alk5fl/þ (g), Alk5fl/fl (h),
Nrp1fl/þ ; Alk1fl/fl (i) or Alk1fl/fl (j) cells at the tip, normalized to overall contribution of cells to the endothelium. Statistical significance was determined by
comparing the proportion of deficient (green) cells at the tip with the total proportion of deficient (green) cells; P¼NS (0.0536) (g), P¼NS (0.7576) (h),
P¼NS (0.275) (i), Po0.0358 (j). n¼ number of retinas analysed; n¼8 (g), n¼4 (h), n¼ 6 (i) and n¼4 (j); values represent mean±s.e.m. Statistical
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the balance between Alk1 and Alk5 signalling has been shown to
regulate vascular function14, and Alk1-mediated Smad signalling
was shown to co-operate with Notch to induce the stalk cell
fate10,11, the relative contributions of Smad1/5/8 and Smad2/3 in
tip/stalk cell specification are not fully understood. pSmad2
staining in the EB system preferentially highlighted stalk cell
nuclei, providing first indications for differential activity. Tgf-b
stimulation, which curbed sprouting, lead to high pSmad2 levels
in all endothelial cells, an effect that was sensitive to the Alk5
inhibitor SB-431542. Together with the observed hypersprouting
phenotype induced by SB-431542, these results suggest that
endogenous Tgf-b signalling drives differential pSmad2 activity
via Alk5 in the endothelium.
Given that we observed little effect of Nrp1 on pSmad1/5/8,
we initially suspected that the prominent role of Bmp/Alk1 in
tip/stalk specification11 would be distinct and not influenced
by Nrp1. However, endothelial cells responded with Smad2/3
phosphorylation even when stimulated with Bmp9, and showed
increased pSmad2/3 in the absence of Nrp1 also under Bmp9
stimulation. These data suggest that tip cell Nrp1 inhibits
Bmp9-Alk1 signalling and implicates Smad2/3 signalling in this
response. The identification of Nrp1 as a modulator of Alk1
signalling output, and the striking normalization of the
hypervascular phenotype in Alk1-deficient retinas by deletion of
a single copy of Nrp1 raises the prospect that targeting Nrp1
activity could provide treatment options for Hereditary
Haemorrhagic Telangiectasia (HHT) patients carrying
inactivating Alk1 mutations58.
How Nrp1 inhibits Smad2/3 signalling remains to be
determined. Nrp1 has been shown to bind latent Tgf-b and to
interact with Alk5 in tumour cells and fibroblasts59,60, suggesting
that Nrp1 might act as a ligand trap in endothelial cells. However,
the fact that soluble Nrp1 fails to inhibit Tgf-b-induced Smad2/3
activation argues against this possibility. Nrp1 might act as a
decoy by virtue of its extracellular or transmembrane domains,
which may inhibit interactions between type 1 and type 2
receptors and Smad phosphorylation. We show that
phosphorylation of the Smad linker region, which negatively
modulates Smad signalling61, is unaffected by Nrp1. Decreased
Nrp1 also failed to affect expression levels of endothelial type 1 or
type 2 receptors, or the co-receptor endoglin (Eng), although it
cannot be excluded that other circulating ligand traps are
modulated by Nrp1. Further studies are required to elucidate
the mechanistic basis for Nrp1 suppression of Smad2/3 signalling
and its interaction with Alk1 and Alk5.
Conceptually, these results radically change the view of Notch
function and tip cell formation. Whereas the prevailing paradigm
presumes that Notch is the critical brake on angiogenesis, as
blocking of Dll4/Notch even in the adult is sufficient to activate
new sprouting and tip cell formation, our results indicate that
instead Smad2/3 signalling is the major constraint on sprouting
and tip cell formation. Notch takes a role as a modulator,
establishing through lateral-inhibition heterogeneity in the
Tgf-b/Bmp–Smad2/3 response. Notch patterns the differential
Smad2/3 response by regulating Nrp1, thus allowing tip/stalk
specification and regular sprouting. Implicit in this view is a
second conceptual shift: the tip cell is not just the default
response, but requires active suppression of the stalk cell
phenotype.
This change in our understanding of the principal mechanisms
regulating endothelial responses has wide implications for
therapy, as Nrp1 inhibition becomes a highly attractive target
to curb angiogenesis, or to modulate Tgf-b/Bmp responses in
vascular malformations.
Methods
Mice. Mice for blastocyst injection were maintained at the London Research
Institute. Animal procedures were performed in accordance with the Home Office
Animal Act 1986 under the authority of project license PPL 80/2391. Mice for
inducible gene deletion were maintained in the Animal Research Center at Yale
University and experiments were approved by the IACUC of Yale University.
The following mouse strains were used: Tg(CAG-DsRED-MST)Nagy/J (Jackson
Laboratory, USA)62, were used as hosts to generate chimeric retinas. C57/Bl6,
mT/mG34 and Nrp1flox31 have been described previously and were obtained from
Jackson Laboratories. Cdh5-CreERT2 mice32,33 were provided by Ralf Adams.
Alk1flox and Alk5flox mice63,64 were kindly provided by Paul Oh and Stefan
Karlsson, respectively.
Inducible gene deletion. Cre activity and gene deletion were induced by
intraperitoneal injections to male and female pups with 100mg tamoxifen (Sigma,
Vegfr2
Vegfr2
Notch
pSmad2/3
pSmad1/5/8
Stalk cell
behaviour
Tgf-β
Bmp9/10
Nrp1
pSmad2/3
pSmad1/5/8
Dll4
Nrp1
Al
k1
Al
k5
Tgf-β
Bmp9/10
Wildtype
Nrp1 knock out
Al
k1
Al
k5
Notch
pSmad2/3
pSmad1/5/8
Stalk cell
behaviour
Tgf-β
Bmp9/10
Dll4
Al
k1
Al
k5
Tgf-β
Bmp9/10
Al
k1
Al
k5
pSmad2/3
pSmad1/5/8
Stalk cell
behaviour
a
b
Figure 8 | Working model for Nrp1 function in tip cell formation. (a) The
data suggest that Nrp1 inhibits Smad2/3 phosphorylation by Alk5 and Alk1
in response to Tgf-b and Bmp9/10 in tip cells (yellow). VEGF-dependent,
but Nrp1-independent upregulation of Dll4 in the tip leads to Notch
activation in stalk cells, which decreases Nrp1 levels in the stalk cell (blue).
The reduction of Nrp1 in the stalk results in higher pSmad2/3 levels and
stalk cell behaviour. (b) In an Nrp1 knock-out situation, pSmad2/3 activation
leads to the activation of stalk cell behaviour in all endothelial cells,
resulting in sprouting inhibition.
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T5648; 2mgml 1) at postnatal day (P) 1, P2 and mice were killed at P5. 30 mg
tamoxifen was injected at P1 to induce mosaic deletion and mice were killed at P5.
Animal procedures. Embryonic stem cells in suspension (see Mouse ES Cells
section) were injected into 3.5-day post-coitum-stage embryos produced by mating
homozygote Tg(CAG-DsRED*MST)1Nagy/J mice to C57BL/6J mice according to
standard protocols after which embryos were reimplanted into pseudopregnant
C57BL/6J foster mice65. Mice were killed at P5 for analysis of retinal vasculature.
DAPT (Sigma, D5942) was subcutaneously injected to male and female pups at
P4 using 20 ml g 1 of 5mgml 1 working solution and mice were killed 24 h later.
For EdU staining (Life Technologies, A10044), male and female mice were
intraperitoneally injected with 20 ml g 1 of 0.5mgml 1 of EdU at P5. Harvest of
the eyes was performed 2 h after EdU injection. Twenty mg kg 1 SB-431542
(Sigma, S4317; 10mgml 1) was intraperitoneally injected in male and female
pups at P3 and P4, and mice were killed at P5.
Retina analysis and quantification. Eyes were harvested at P5 and fixed with 4%
paraformaldehyde on ice for 2 h, or at room temperature for 18min, followed by
retinal dissection before staining was performed. Whole mount was performed
using VectaShield mounting media (Vector Laboratories).
High-resolution three-dimensional rendering of retinas and embryoid bodies
were acquired using a Laser Scanning Microscope 780 confocal system (Zeiss),
using the ZEN 2010B SP1 software, version 6.0 (Zeiss) or a Leica SP5 confocal
microscope using a Leica spectral detection system (Leica SP detector) and the
Leica application suite advanced fluorescence software.
Mouse ES cells. Mouse ES cells expressing DsRED-MST62 were a kind gift
from A. Nagy and J. Rossant (Samuel Lunenfeld Research Institute, Canada).
Vegfr2þ /egfp ES cells were kindly provided by A. Medvinsky (Edinburgh, UK)7.
Nrp1Lacz/þ and Nrp1Lacz/LacZ cells were generated by replacing exons 1 and 2
with a LacZ cassette through homologous recombination66 (Regeneron
Pharmaceuticals).
Embryoid bodies (EBs). Culturing of mouse ES cells and generation of EBs was
performed as described below and as previously described67. ES cell clones were
cultured in DMEM/glutamax (Invitrogen), 25mM HEPES, 1.2mM sodium
pyruvate, 19mM monothioglycerol (Sigma), 15% fetal bovine serum and 1,000
units per ml leukaemia inhibitory factor on gamma-irradiated feeder cells.
Different genotypes were mixed as indicated in the individual figures and left in
suspension as hanging drops without the leukaemia inhibitory factor (Millipore,
ESG1107) (day 0). After 5 days, the formed spheroids were embedded in a
polymerized collagen I gel and stimulated with 30 ngml 1 VEGFA165 (Peprotech,
450-32) to grow in a three-dimensional fashion. The collagen solution was
prepared using 50% 3mgml 1 collagen I (Purecol), 34.65% 1 F-12 Nutrient
Mix (Gibco), 0.625% 100 Glutamax (Gibco), 0.977% sodium bicarbonate 7.5%
(Gibco), 1.25% 1M HEPES (Gibco), 6.25% 10 F-12 Nutrient Mix (made in
house) and 6.25% 0.1N NaOH (Sigma).
Medium with dimethylsulphoxide (Sigma, D4540), 5mM DAPT (Sigma,
D5942), 2 ngml 1 TGF-b (PeproTech, 100-21C) or 10mM SB-431542 (Tocris,
1614) was changed on day 6 and every day thereafter. At day 10, EBs were fixed in
4% paraformaldehyde at room temperature for 15min.
EBs used for protein and RNA extraction were grown on six-well plates
incubated with 0.2% gelatine (Sigma, G1393) after 5 days of hanging drops and
stimulated with 30 ngml 1 VEGFA165 (Peprotech, 450-32). Samples were
harvested after 4 days at day 9 using the respective lysis buffer for RNA or protein
extraction.
Antibodies. For immunostaining and western blotting (WB), the following anti-
bodies were used: goat anti-mouse Nrp1 (1:500; R&D, AF566), rabbit anti-human
Nrp1 (1:1,000, Cell Signaling, 3,725), mouse anti-Smad2/3 (1:500; BD, 610,843),
rabbit anti-pSmad2 (Ser465/467) (1:500; Millipore, 04-953), rabbit anti-pSmad2/3
(Ser465/467 Ser423/425) (1:1,000; Cell Signaling, 9,510), rabbit anti-pSmad2
(Ser245/250/255) (1:1,000; Cell Signaling, 3,140), rabbit anti-pSmad3 (Ser423/425)
(1:500; Abcam, ab52903), rabbit anti-Smad3 (1:500; Abcam, ab40854), rabbit
anti-pSmad1/5/8 (Ser463/465 Ser426/428) (1:1,000; Cell Signaling, 9,511), rabbit
anti-Smad1 (1:1,000; Cell Signaling, 9743), rat anti-Pecam antibody (1:50; BD
Pharmingen, 550274), goat anti-mouse Dll4 (1:200 for immunohistochemistry
analysis and 1:500 for WB; R&D, AF1389), rabbit anti-Erg1/2/3 (1:200, Santa Cruz,
sc-353), Nicd (1:500, Cell Signaling, 2421), mouse anti-a-tubulin (1:5000, Sigma,
T5168), mouse anti-HIS-tag (1:1,000, Abcam, ab18184) and rabbit anti-GFP
(1:1,000; Invitrogen, G10362).
Secondary antibodies: Alexa-488 donkey anti-goat IgG (A11055), Alexa-488
donkey anti-rabbit (A21206), Alexa-647 donkey anti-rabbit IgG (A31573),
isolectin-B4 directly conjugated to Alexa-488 (I21411), all diluted 1:500, obtained
from Life Technologies. Alexa-647 donkey anti-rat (1:500, Stratech Scientific,
712-606-153-JIR). Horseradish peroxidase (HRP)-conjugated anti-rabbit IgG
(1:8,000; GE-Healthcare; NA3940), HRP-conjugated anti-mouse IgG and
HRP-conjugated, (1:8,000; GE-Healthcare; NA931V). Rabbit anti-goat IgG
(1:2,000; Dako; P0449).
Western blotting. Cells were lysed in D0.4 lysis buffer including phosphatase and
protease inhibitors (Thermo Scientific, 78420, 1862209). BCA protein assay
(Fisher, 13276818) was used to measure the protein concentration. Equal amounts
of proteins were separated on NuPAGE 4–12% MOPS gel (Life Technologies,
NP0336) and transferred on polyvinylidene difluoride membrane (GE Healthcare
Biosciences, RPN2020F). WBs were developed with chemiluminescence HRP
substrate (Millipore, WBKLS0500) on a Luminescent image analyser, ImageQuant
LAS 4000 mini (GE Healthcare). Band intensity was measured using ImageQuant
TL 1D, version 7.0.
Quantitative real-time PCR. Primary endothelial cells were isolated from mouse
lung by digestion of lung tissue with gentle agitation at 37 C in PBS with
2mgml 1 type 1 collagenase (Sigma), followed by filtration through a 70-mm
disposable cell strainer (Falcon). Endothelial cells were isolated using rat-anti-
mouse Dynabeads (Life Technologies) coated with anti-PECAM antibody,
according to manufacturer’s instructions. RNA from HUVEC or from primary
endothelial cells isolated from lung68 was extracted and purified using RNeasy-kit
(Qiagen). RNA concentrations were measured on a Nanodrop and adjusted
equally, followed by reverse transcription by SuperScript III (Invitrogen).
Quantitative PCR with Taqman probes for mDll4 (Mm00444619), mCd31
(Mm01242584), mNrp1 (Mm00435379), mNotch1 (Mm00435245), mHey1
(Mm00468865), mAlk1 (Mm_Acvrl1_1_SG QT00161434), mAlk2
(Mm_Acvr1_1_SG QT00093422), mAlk3 (Mm_Bmpr1a_1_SG QT01057511),
mAlk4 (Mm_Acvr1b_1_SG QT00163464), mAlk5 (Mm_Tgfbr1_1_SG
QT00135828), mAlk6 (Mm_Bmpr1b_1_SG QT00121240), mAlk7
(Mm_Acvr1c_1_SG QT00262591), mBmpR2 (Mm_Bmpr2_1_SG QT00251349),
mTgfBR2 (Mm_Tgfbr2_1_SG QT00135646), mEng (Mm_Eng_1_SG
QT00148981), hSMAD6 (Hs00178579), hHES1 (Hs00172878), hID1
(Hs03676575), hAPLN (Hs00178579), hHEY1 (Hs01114113), hID3 (Hs00171409),
GAPDH (4326317E), hNRP1 (Hs00826128), hALK1 (Hs_Acvrl1_1_SG
QT00050351), hALK2 (Hs_Acvr1_1_SG QT00071743), hALK3
(HS_Bmpr1a_1_SG QT00085358), hALK4 (Hs_Acvr1b_1_SG QT00053235),
hALK5 (Hs_Tgfbr1_1_SG QT00083412), hALK6 (Hs_Bmpr1b_1_SG
QT00084469), hAlk7 (Hs_Acvr1c_1_SG QT00042819), hBMPR2
(Hs_Bmpr2_1_SG QT00226065), hTGFBR2 (Hs_Tgfbr2_1_SG QT00014350) and
hENG (Hs_Eng_1_SG QT00013335) were run in an Applied Biosystems 7900HT
real-time thermal cycler. The expression levels were normalized to Pecam for EBs
and to GAPDH for HUVECs.
Sprouting assay. HUVECs were transfected with 25 pmol siRNA (FlexiTube
siRNA, Qiagen) per well of a six-well plate using 2.5ml RNAiMax (Invitrogen)
according to the manufacturer’s instructions. After 24 h, HUVECs were labelled
with either PKH26 (red) or PKH67 (green) (Sigma-Aldrich) according to the
manufacturer’s instructions, and a ratio of 1:1 cells were coated on cytodex3
microcarrier beads (Sigma-Aldrich) for 24 h. Beads were embedded in a fibrin gel
(2.5mgml 1 fibrinogen (Sigma-Aldrich) in EBM-2 (Lonza) supplemented with
2% FBS and 50mgml 1 aprotinin (Sigma-Aldrich)) with fibrinogen solution
clotted with 1U thrombin (Sigma-Aldrich) for 30min at 37 C. WI38 cells (25,000
cells per well), in EBM-2 supplemented with 2% FBS and 50 ngml 1 VEGF, were
then plated on top of the fibrin layer. Sprouts were imaged 3–4 days later on a
Nikon eclipse Ti confocal microscope with the PerkinElmer UltraVIEW Confocal
Imaging System and PerkinElmer Volocity software.
Cell culture experiments. HUVECs (PromoCell) were cultured in EGM2-
Bulletkit (Lonza), following the manufacturer’s manual, and used for all experi-
ments at passage 2–4. SiRNA transfection for NRP1 (J-019484-06), VEGFR2
(J-003148-09) and control siRNA (D-001810-01), ALK1 (#M-005302-02), ALK5
(#M-003929-02), SMAD2 (#M-003561-01) and SMAD3 (#M-020067-00), all
obtained from Dharmacon, was performed 48 h prior harvesting using Dharmafect
1 (Dharmacon), following the provided manual. NRP1 plasmids (pEGFP-
N1_mNRP1, pEGFP-N1_mNRP1dSEA and pEGFP-N1_mNRP1dCY) have been
a kind gift from Dr Guido Serini (IRCC, Institute for Cancer Research and
Treatment and Department of Oncological Sciences, University of Torino School
of Medicine). Transient transfection was performed using Lipofectamin 2000
(Invitrogen) for 24 h prior harvesting. Cells were treated with 10mM recombinant
NRP1 (R&D, 5994-N1), 2 ngml 1 TGF-b (R&D and PeproTech), SB-431542
(Sigma and Tocris), 10 ngml 1 BMP9 (R&D) or 5 mM DAPT (Calbiochem and
Sigma).
Image segmentation. Confocal images of chimeric retinas obtained from
blastocyst injection were processed in Imaris 7.6.1 (Bitplane). Using the endothelial
marker Pecam, a surface mask was created to subtract endothelial cells from
background signal. Within the Pecam mask a second surface mask was generated
using the DsRED signal expressed by wt cells. The DsRED mask was used to
separate Erg-positive nuclei within the DsRED mask from Erg-positive nuclei
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outside the DsRED mask but inside the Pecam mask. Using pseudo-colours both
sets of Erg signals were highlighted in different colours as indicated in the figure.
Statistical analysis and image processing. Student’s unpaired t-tests for
comparison were performed for all quantitative data, if not indicated differently,
using Prism 6.0 (Graph Pad), Excel (Microsoft). Image processing was performed
using Imaris 7.6.1 (Bitplane), Volocity 5.5 (Perkin Elmer) and Photoshop CS5
(Adobe), in compliance with ‘Nature Press Data Processing Policy’.
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